Webinar Date/Time: Tuesday, March 14 2023, 9 am CT, 10 am ET, 3 pm GMT, 4 pm CET
As clinical research and pharmacovigilance operations move away from multiple technology vendors that supply solutions on a myriad of infrastructures requiring costly integrations that do not deliver interoperability, they need a proven technology vendor committed to their success and guided by industry expertise.
Register Free: https://www.pharmexec.com/pe_w/transformational
Event Overview:
As clinical research and pharmacovigilance operations move away from multiple technology vendors that supply solutions on a myriad of infrastructures requiring costly integrations that do not deliver interoperability, they need a proven technology vendor committed to their success and guided by industry expertise.
Learn how Oracle helps enable you to realize the value of your investments throughout the complete clinical trial continuum. This journey, including business assessments, best practices, enablement, mentoring, industry peer interaction, and professional services, allows you to drive greater value from Oracle and our partner ecosystem.
Key Learning Objectives:
Speakers:
Ryan Kennedy
Global VP, product Strategy, Experience, and Enablement
Oracle
Ryan Kennedy is the Global VP of Product Strategy, Experience, and Enablement for Oracle Health and AI. Ryan has 22 years of clinical research experience ranging from direct site and patient management at University of Pittsburgh’s Cancer Center to eCOA and eClinical technology development. He has a Bachelor’s in Philosophy and Neuroscience from Allegheny College and an MBA from the Katz School of Business, University of Pittsburgh.
Sean Roy
Senior Consulting Practice Director
Oracle
Sean Roy is the Senior Director of North America Services for Oracle’s Health Sciences Global Business Unit. Sean has 10 years of IRT/RTSM domain expertise and 14+ years’ experience in the services delivery of clinical trial software. Sean holds a BS in Management from Bentley University, a MS in Leadership from Northeastern University, and a PhD in Organizational Leadership from Indiana Wesleyan University.
Drew Zwiebel
Global Vice President, Alliances & Channels
Oracle
Drew Zwiebel has been in the IT and Professional Services industries for 28+ years and has deep industry experience in global healthcare and life sciences, having worked closely with governments, national health agencies, health systems, pharma, biotech, CROs, global system integrators, and independent software providers. Mr. Zwiebel is currently Global Vice President, Alliances & Channels, for Oracle’s Health Sciences Global Business Unit, where he is responsible for globally managing the collaboration and go-to market strategies with an ecosystem of partners focused on Oracle’s Health Sciences product portfolio. He has successfully helped define and execute strategies as key competitive differentiators for some of the world’s leading, best known, and highest growth companies.
Prior to Oracle, Mr. Zwiebel held various management positions with PPD, one of the world’s leading Contract Research Organizations, and was responsible for the development and successful launch of their Global eClinical Technology Division. This is in addition to holding various management positions with prior companies in areas of strategy, marketing, and business development. Mr. Zwiebel is a graduate of the Williams College, a Board Member of the University of Washington School of Education’s Haring Center, a previous Board Member of Education First, a national 501c3, and a member of the Association of Strategic Alliances Professionals.
Raj Modi
Senior Director, Global Customer Centre of Excellence
Oracle
Raj Modi has over 20 years’ experience in strategy and transformation consulting, working for a range of clients within pharmaceutical, med device, public health, insurance industries and start-ups. As an ex-strategic consultant who operated at board level, he often led the formulation and implementation of business strategies. His role at Oracle is to respond to and stimulate change at senior levels for Oracle’s most important customers.
Register Free: https://www.pharmexec.com/pe_w/transformational
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.